OPTH Optimi Health Corp.
$4.42▼ -1.78%
Healthcare
Other
After hours
$4.32▼ -2.26%
Sep 11, 7:30 PM ET
Volume 36.9K
Avg Volume (10D) 70.3K
Key Metrics & Fundamentals
Market Cap
$25.31M
P/E Ratio
–
Div Yield
–%
52W Range
4.00 - 6.40
% vs 50 MA
-7.41%
% vs 200 MA
–%
RSI-14
39.1
MACD Histogram
-0.0500
Beta (1Y vs SPY)
1.87
Free Cash Flow
-$2.87M
Gross Rev
$140,200
Gross Profit
$66,623
EBITDA
-$1.90M
COGS
$73,577
Operating Exp
$2.20M
Operating Income
-$2.13M
EBIT
-$2.13M
Pretax Income
-$2.40M
Net Income
-$2.40M
EPS (Diluted)
-0.56
Price & Volume History
Loading chart…
Recent News
Optimi Health to Start Phase 2 Trial of Psilocybin-Assisted Therapy for Major Depressive Disorder in H1 2027
MT Newswires · Sep 10, 2026 2:57 PM
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
GlobeNewswire · Sep 10, 2026 12:45 PM
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 8, 2026 12:30 PM
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Market Exclusive · Aug 31, 2026 2:12 PM
3 Revenue Generating Psychedelics Stocks Retail Investors Are Screening Right Now
Simply Wall St. · Aug 21, 2026 5:16 AM
Optimi Health Establishes $100 Million Equity Facility as Psychedelic Commercialisation Advances
Simply Wall St. · Aug 19, 2026 6:03 AM
Optimi Health Establishes Discretionary Equity Facility
GlobeNewswire · Aug 14, 2026 8:55 PM
3 Psychedelic Stocks With Potential Clinical Trial Catalysts
Simply Wall St. · Jul 10, 2026 6:21 AM
Optimi Health Makes Third Commercial Shipment of Psilocybin for Treatment-Resistant Depression to Australia
MT Newswires · Jun 29, 2026 3:49 PM
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
PR Newswire · Jun 29, 2026 3:13 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See OPTH's money flow as a full page
Social Sentiment
No Reddit posts found for OPTH.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.